US Pharma MarketingThe post BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint appeared first on Clinical Trials Arena.
BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint
BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency, met one co-primary endpoint. The trial showed that BMN 401 increased plasma PPi levels through week 52 versus the control group. The study did not meet the second co-primary endpoint, showing no improvement in Radiographic Global Impression of Change scores. Credit: PeopleImages / Shutterstock.com. BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency…
BioMarin Pharmaceutical has reported that its pivotal Phase III ENERGY 3 trial assessing BMN 401 in children aged one to 12 years with ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) deficiency, met one co-primary endpoint.
Source: Clinical Trials Arena